Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


25. March 2021 | 08:19 CET

Evotec, PsyBio Therapeutics, MorphoSys - Milestone in Development!

  • Biotechnology
Photo credits: pixabay.com

About 350 million people worldwide live with depression. According to estimates by the World Health Organization (WHO), only one in four sufferers receives adequate treatment. With all its limitations, the Corona Crisis has caused the number of unreported cases to skyrocket exorbitantly, making depression the most significant cause of illness above all. Apart from the prescription of antidepressants, which usually have strong side effects, there are few alternative treatment methods. But now, young biotech companies are stepping up to revolutionize the field of "mental health."

time to read: 3 minutes by Stefan Feulner
ISIN: DE0005664809 , CA6936971044 , DE0006632003


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Long history

Currently, "magic mushrooms" are one of the hippest topics on the stock markets. But the history of mushrooms containing psychedelic substances goes back thousands of years. The Aztecs of Mexico already used the psilocybin-containing mushrooms for ritual and profane purposes as intoxicating drugs. But it was not until 1957 that Albert Hofmann, who had already discovered LSD, was the first to isolate psilocybin and psilocin as the active substances of the mushroom. The chemical structures of the main active substances are closely related to LSD, so they also produce similar psychoactive effects. In the 1960s, synthetically produced psilocybin was marketed under the name Indocybin® by the pharmaceutical Company Sandoz for experimental and psychotherapeutic purposes. The increasing use as a narcotic drug, especially by representatives of the hippie movement, was cited as one of the reasons for the prohibition of LSD and other psychedelics in the early 1970s.

Revolutionary approaches

For many years, there has been an increasing number of studies with volunteers to investigate the possible therapeutic effects of drugs, such as psilocybin or LSD. These studies are looking at the use of psilocybin and other hallucinogens to treat a range of otherwise untreatable mental disorders, such as chronic depression, post-traumatic stress disorder, and drug or alcohol addiction. Now, PsyBio Therapeutics aims to bring a unique drug to market. In cooperation with the University of Miami's Department of Psychology, the Canadians are working with other related active ingredients, investigating their interactions, and researching substances that work even better than pure psilocybin. This collaboration has already yielded several patents.

Global leader

According to PsyBio CEO Evan Levine, the Company is in pole position regarding research and patent prosecution in the industry. The Company also has a unique selling proposition, which should significantly impact margins in the future. The Company recently filed a process patent that can produce psilocybin using bacteria significantly cheaper, faster and more environmentally friendly than any other published method.

Earlier this week, PsyBio was able to announce another important step. It was able to start developing its second product candidate, a proprietary biosynthetic formulation of norbaeocystin, in collaboration with the Advanced Biofuels and Bioproducts Process Development Unit. Norbaeocystin is an analog of psilocybin and is not a controlled substance. The Company has begun Phase 1 of this process, including the technical transfer of analytical chemistry to identify capture methods for fermentation products as well as key feedstock and metabolites. PsyBio shares were listed on the Canadian Stock Exchange in late February and are also tradable in Frankfurt. The market capitalization is around CAD 40 million. A bet on the future.

You can read the full interview with PsyBio Therapeutics CEO Evan Levine here: Interview Evan Levine

Promising cooperation

The German biotech Company Evotec has announced the successful conclusion of a partnership. The Japanese pharmaceutical Company Takeda Pharmaceutical Company Limited may use Evotec's RNA platform to identify promising RNA sequences to target small molecule ligands that can be further developed into potential first-in-class therapeutics. In return, Evotec will collect research payments and can expect to receive early-stage, preclinical, clinical and commercial milestone payments of up to the equivalent of EUR 134 m per program. In addition, Evotec is entitled to staggered royalties on the products' net sales resulting from this collaboration. Chart-wise, the stock is facing a decision at the moment. A break of the EUR 30 support would generate a sell signal. We advise investors to wait and see.

Negative signs

The MorphoSys share has already broken the support. Since its high at the start of the year, the stock has corrected by just under 50% and was quoted at EUR 75 yesterday. The correction is likely to extend to the next target point at around EUR 70. We currently advise against an investment. Also, fundamentally, we do not see MorphoSys as a buy candidate at the moment. The weak outlook for the full year 2021 still causes uncertainty.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read